Patents Assigned to Brigham and Women's Hospital
  • Patent number: 10125116
    Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: November 13, 2018
    Assignees: Brandeis University, University of Georgia Research Foundation, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Sivapriya Kirubakaran, Sushil K. Maurya, Boris Striepen, Suresh K. Gorla, Corey R. Johnson, Mandapati Kavitha, Jihan Khan
  • Patent number: 10119168
    Abstract: The technology described herein is directed to the diagnosis, prognosis, and treatment of kidney fibrosis, e.g., chronic kidney disease.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: November 6, 2018
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vishal S. Vaidya, Florin Craciun, Amrendra K. Ajay
  • Patent number: 10119169
    Abstract: Methods for diagnosing and treating Müllerian Adenosarcoma that include detecting the presence of one or more of a mutation in an ATRX gene, and/or a Copy Number Variation (CNV) in a MYBL1, MDM2, HMGA2, and/or CDK4 gene.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: November 6, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Brooke Howitt, Bradley Quade, Marisa Nucci, Lynette Sholl
  • Publication number: 20180311356
    Abstract: Embodiments herein provide for compositions and methods for inhibiting pathological endothelial-to-mesenchymal transition (EndMT), e.g., in endothelial cells and in a mammal. Specially, pathological EndMT can be inhibited by inhibiting CD45, either protein activity or protein expression or both, and optionally also inhibiting TGF-?. Compositions comprising a CD45 inhibitor, a CD45 inhibitor and a TGF-? inhibitor, or a CD45 inhibitor, a TGF-? inhibitor and an anti-fibrosis agent are disclosed.
    Type: Application
    Filed: October 19, 2016
    Publication date: November 1, 2018
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Joyce E. BISCHOFF, Robert A. LEVINE, Elena AIKAWA
  • Patent number: 10111847
    Abstract: Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that fmd use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions fmd use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: October 30, 2018
    Assignees: The Regents of the University of California, The Brigham and Women's Hospital, Inc.
    Inventors: Michael S. Conte, Charles N. Serhan, Tejal A. Desai
  • Patent number: 10107823
    Abstract: Systems and methods for imaging of matrix vesicle-derived calcification are described. In one embodiment, the method comprises raising the pH of collagen stored in a solution, thereby causing the collagen to come out of the solution to form a network, adding matrix vesicles to the network, resulting in calcifications, and imaging the formation of the calcification. The calcification process can be imaged in real time by confocal or reflected light microscopy.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: October 23, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Joshua Daniel Hutcheson, Elena Aikawa, Masanori Aikawa
  • Publication number: 20180298095
    Abstract: Described herein are compositions and methods for modulating immune response, which can be upregulated or down regulated by enhancement or inhibition of interactions between CEACAM family members and TIM family members.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 18, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG, Yasuyuki KONDO, Amit GANDHI
  • Publication number: 20180298446
    Abstract: The invention provides a collection of gene expression signatures that is linked to longevity. Also provided herein are assays, methods, and systems for identifying a treatment that can modulate lifespan or determining an effect of a treatment on a health profile of a subject by using the collection of gene expression signatures described herein.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 18, 2018
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventor: Vadim Gladyshev
  • Patent number: 10100367
    Abstract: The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 16, 2018
    Assignees: The Regents of the University of California, The Brigham and Women's Hospital, Inc.
    Inventors: Anna M. Krichevsky, Nadiya Teplyuk, Santosh Kesari, Brit Mollenhauer
  • Patent number: 10092627
    Abstract: Methods and compositions for rejuvenating skeletal muscle stem cells are disclosed.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: October 9, 2018
    Assignees: President and Fellows of Harvard College, The Brigham and Womens's Hospital, Inc.
    Inventors: Amy J. Wagers, Richard T. Lee
  • Patent number: 10092253
    Abstract: An imaging system for imaging a portion(s) of an anatomical structure can be provided. For example, an x-ray source first arrangement can provide x-ray radiation, and a multi-hole collimator second arrangement can be provided in a path of the x-ray radiation, and can be configured to undersample the radiation beam which can be forwarded to the portion(s) of the anatomical structure. A third hardware arrangement can be configured to receive a further x-ray radiation from the portion(s) that can be based on the undersampled x-ray radiation.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 9, 2018
    Assignees: NEW YORK UNIVERSITY, BRIGHAM AND WOMEN'S HOSPITAL
    Inventors: Daniel K. Sodickson, Aaron Sodickson, Ricardo Otazo
  • Publication number: 20180271978
    Abstract: Compositions and methods for the radiological and immunotherapeutic treatment of cancer are provided. Metallic nanoparticles conjugated with an immunoadjuvant are dispersed within a biodegradable polymer matrix that can be implanted in a patient and released gradually. The implant may be configured as, or be a component of, brachytherapy spacers and applicators, or radiotherapy fiducial markers. The composition may be combined with marginless radiotherapy, allowing for lower doses of radiation and enhancing the immune response against cancer, including at non-irradiated sites.
    Type: Application
    Filed: August 15, 2016
    Publication date: September 27, 2018
    Applicants: Northeastern University, Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Wilfred Ngwa, Rajiv Kumar, Gerassimos Makrigiorgos, Srinivas Sridhar, Stephanie Dougan
  • Publication number: 20180271977
    Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 27, 2018
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
  • Publication number: 20180271886
    Abstract: Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors.
    Type: Application
    Filed: March 14, 2018
    Publication date: September 27, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jane YU, Chenggang LI
  • Publication number: 20180258404
    Abstract: The Inventors established an efficient, chemically defined protocol for differentiating hPSCs into multi-potent nephron progenitor cells (NPCs) that can form nephron-like structures. By recapitulating metanephric kidney development in vitro, the Inventors generate SIX2+SALL1+WT1+PAX2+ NPCs with 90% efficiency within 9 days of differentiation. The NPCs possess the developmental potential of their in vivo counterparts and form PAX8+LHX1+ renal vesicles that self-pattern into nephron structures. In both 2D and 3D culture, NPCs form kidney organoids containing epithelial nephron-like structures expressing markers of podocytes, proximal tubules, loops of Henle, and distal tubules in an organized, continuous arrangement that resembles the nephron in vivo. The Inventors also show that this organoid culture system can be used to study mechanisms of human kidney development and toxicity.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 13, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Joseph V. Bonventre, Ryuji Morizane
  • Publication number: 20180245050
    Abstract: Human pluripotent stem cells (hPSCs) have dual value as microphysiological laboratory models and regenerative therapeutics. hPSCs are epithelial cells, but the extent to which hPSCs and descendant epithelia can reconstitute lineage-specific functions remains poorly understood. Here the Inventors show that hPSCs in three-dimensional cultures and their differentiated descendants can functionally recapitulate tissue-specific epithelial morphogenesis, physiology, and disease.
    Type: Application
    Filed: September 2, 2016
    Publication date: August 30, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin S. Freedman, Joseph V. Bonventre
  • Patent number: 10060920
    Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: August 28, 2018
    Assignees: Howard Hughes Medical Institute, The Brigham & Women's Hospital, Inc.
    Inventors: Jonathan S. Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
  • Publication number: 20180231554
    Abstract: Described herein are biomarkers comprising mTOR, PI3K/AKT, and MAPK/ERK signaling pathway members as well as cap-dependent translation initiation factors that enable monitoring and predicting responses to PD-1 pathway blockade in patients afflicted with cancers characterized by PD-1 expression.
    Type: Application
    Filed: September 2, 2016
    Publication date: August 16, 2018
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Tobias SCHATTON, Sonja KLEFFEL, Christian POSCH
  • Patent number: 10046023
    Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 14, 2018
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
    Inventors: Richard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin McDonnell, Rosa Maria Silva Garcia Grenha
  • Patent number: 10041046
    Abstract: Described are cell culture solutions and systems for epithelial stem cell and organoid cultures, formation of epithelial constructs and uses of the same in transplantation. A single layer of epithelial cells that actively self-renews and is organized into crypts and villi clothes the intestine. It has been recently shown that the renewal of intestinal epithelium is driven by Lgr5+ intestinal stem cells (ISC) that reside at the base of these crypts (Barker et al., 2007). Lgr5+ stem cells can be isolated and cultured in vitro to form organoids containing crypt-vcllus structures that recapitulates the native intestinal epithelium (Sato et al., 2009).
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 7, 2018
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Jeffrey Michael Karp, Xiaolei Yin, Marc David Succi, Robert Samuel Langer